Trial failures put onus on Roche

The pressure's on at Roche. Some months into its full ownership of Genentech, Roche has seen a couple of setbacks in its development program for that "pipeline-in-a-drug," Avastin. Will it fare any better with its future efforts to broaden Avastin use? Can it win new indications for Avastin's fellow cancer med Herceptin? What about Rituxan/MabThera?

Executives will seek to quell any fears about these efforts at a meeting Thursday. Analysts are looking for reason to believe, the Wall Street Journal reports. "Roche will have to prove that with the takeover of Genentech it can turn into a real leader in pharma and biotechnology," Zuercher Kantonalbank analyst Michael Nawrath told the paper. "[I]t needs to prove it can produce growth out of these candidates."

New indications are important for Avastin, Herceptin and Rituxan to keep those three key meds growing; after all, they represent more than one-third of the company's sales. Analysts will be looking for info on how much Roche expects these three drugs to grow--this year and as time goes on. The company will also talk about its experimental drugs. Stay tuned later this week for an update.

- read the WSJ piece

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.